secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001104659-25-018717
Event type: regulatory
Sentiment:  neutral
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA
------------------------------------------------------

- Resubmitted Biologics License Application for ONS-5010 to FDA on February 28, 2025.
- No details on resubmission content, prior FDA actions, or expected review timeline provided.
- Resubmission marks a key regulatory step for the company's sole pipeline candidate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925018717/0001104659-25-018717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925018717/tm257885d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer